NO20060190L - <n-pyrrolidin-3-ylamide derivatives as serotonin and norepinephrine reuptake inhibitors - Google Patents
<n-pyrrolidin-3-ylamide derivatives as serotonin and norepinephrine reuptake inhibitorsInfo
- Publication number
- NO20060190L NO20060190L NO20060190A NO20060190A NO20060190L NO 20060190 L NO20060190 L NO 20060190L NO 20060190 A NO20060190 A NO 20060190A NO 20060190 A NO20060190 A NO 20060190A NO 20060190 L NO20060190 L NO 20060190L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- alkoxy
- aryl
- het
- cycloalkyl
- Prior art date
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract 4
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 title abstract 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 title abstract 2
- 229940076279 serotonin Drugs 0.000 title abstract 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 19
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
Abstract
Forbindelse med formel (I) og farmasøytisk og/eller veterinærakseptable derivater derav, hvori R' er H, Ci-ealkyl, -C(X)Y, C3.«cykloalkyl, atyl, het, atyl-Ci.4alkyl, eller het-Ci.4alkyl, hvori cykloalkyl, aryl eller hetgmppene er eventuelt substituert med minst en substituent uavhengig valgt fra Ci.8allyl, Ci.8alkoksy, OH, halo, CF3, OCF3, SCF3, hydroksy-Ci.6alkyl, Ci-4alkoksy-Ci.6alkyl og Ci.4alkyl-S-Ci.4alkyl; R^ er atyl eller heteroaryl, hver eventuelt substituert med minst en subtituent uavhengig valgt fra Ci.galkyl, Ci.galkoksy, OH, halo, CF3, OCF3, SCF3, hydroksy-Ci-ealkyl, Ci.4.alkoksy-Ci.6alkyl og Ci.4alkyl-S-Ci.4alkyl; R^ er Ci-ealkyl, C3.8cykloalkyl,C3-8cykloalkyl-Ci.6alkyl, aryl, het, aiyl-Ci.4alkyl, eller het-Ci.4alkyl, hvori cykloalkyl, aryl eller hetgmppene er eventuelt substituert med minst en substituent uavhengig valgt fra Ci-ealkyl, Cuealkoksy, OH, halo, CF3, OCF3, SCF3, hydroksy-Ci.6alkyl,C i.4alkoksy-Ci.6alkyl og Ci.4alkyl-S-Ci.4alkyl; X er S eller O; Y er H, Ci.6alkyl, Ci.6alkoksy, aryl, het, aryl-Ci.4alkyl eller het-Ci.4alkyl; n er 1 eller 2, fomtsatt at når n er 1, er m 0 eller 2 og n er 2, er m 0, hvori hvis m er 0, da representerer * et kiralt senter. Forbindelsene ifølge oppfinnelsen fremviser aktivitet som både serotonin og noradrenalingjenopptagningsinhibitorer og har derfor anvendelse innenfor et antall terapeutiske områder, for eksempel urininkontinens.A compound of formula (I) and pharmaceutically and / or veterinarily acceptable derivatives thereof wherein R 1 is H, C 1-6 alkyl, -C (X) Y, C 3-6 cycloalkyl, atyl, het, atyl-C 1-4 alkyl, or hetero- C 1-4 alkyl, wherein the cycloalkyl, aryl or het group is optionally substituted with at least one substituent independently selected from C 1-8 allyl, C 1-8 alkoxy, OH, halo, CF 3, OCF 3, SCF 3, hydroxy-C 1-6 alkyl, C 1-4 alkoxy-C 1. 6alkyl and C1-4alkyl-S-C1-4alkyl; R 1 is atyl or heteroaryl, each optionally substituted with at least one subtituent independently selected from C 1-6 alkyl, C 1-4 alkoxy, OH, halo, CF 3, OCF 3, SCF 3, hydroxy-C 1-6 alkyl, C 1-4 alkoxy-C 1-6 alkyl and C 1-4 alkyl-S-C 1-4 alkyl; R 1 is C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl C 1-6 alkyl, aryl, het, aryl-C 1-4 alkyl, or het-C 1-4 alkyl, wherein the cycloalkyl, aryl or hete groups are optionally substituted with at least one substituent independently selected from C 1-6 alkyl, Cualkoxy, OH, halo, CF 3, OCF 3, SCF 3, hydroxy-C 1-6 alkyl, C 1-4 alkoxy-C 1-6 alkyl and C 1-4 alkyl-S-C 1-4 alkyl; X is S or O; Y is H, C 1-6 alkyl, C 1-6 alkoxy, aryl, het, aryl-C 1-4 alkyl or het-C 1-4 alkyl; n is 1 or 2, assuming that when n is 1, m is 0 or 2 and n is 2, m is 0, wherein if m is 0, then * represents a chiral center. The compounds of the invention exhibit activity as both serotonin and norepinephrine reuptake inhibitors and therefore have utility in a number of therapeutic areas, for example urinary incontinence.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0314048.0A GB0314048D0 (en) | 2003-06-17 | 2003-06-17 | Novel compounds |
| PCT/IB2004/001943 WO2004110995A1 (en) | 2003-06-17 | 2004-06-07 | N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20060190L true NO20060190L (en) | 2006-01-12 |
Family
ID=27636730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060190A NO20060190L (en) | 2003-06-17 | 2006-01-12 | <n-pyrrolidin-3-ylamide derivatives as serotonin and norepinephrine reuptake inhibitors |
Country Status (9)
| Country | Link |
|---|---|
| CN (1) | CN1835921A (en) |
| GB (1) | GB0314048D0 (en) |
| GT (1) | GT200400121A (en) |
| NO (1) | NO20060190L (en) |
| OA (1) | OA13178A (en) |
| RS (1) | RS20050924A (en) |
| TN (1) | TNSN05321A1 (en) |
| UA (1) | UA80338C2 (en) |
| ZA (1) | ZA200509132B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI434690B (en) * | 2007-12-19 | 2014-04-21 | Dainippon Sumitomo Pharma Co | Heterobicyclic derivatives |
-
2003
- 2003-06-17 GB GBGB0314048.0A patent/GB0314048D0/en not_active Ceased
-
2004
- 2004-06-07 RS YUP-2005/0924A patent/RS20050924A/en unknown
- 2004-06-07 CN CNA2004800172229A patent/CN1835921A/en active Pending
- 2004-06-07 OA OA1200500363A patent/OA13178A/en unknown
- 2004-06-15 GT GT200400121A patent/GT200400121A/en unknown
- 2004-07-06 UA UAA200511011A patent/UA80338C2/en unknown
-
2005
- 2005-11-11 ZA ZA200509132A patent/ZA200509132B/en unknown
- 2005-12-16 TN TNP2005000321A patent/TNSN05321A1/en unknown
-
2006
- 2006-01-12 NO NO20060190A patent/NO20060190L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UA80338C2 (en) | 2007-09-10 |
| CN1835921A (en) | 2006-09-20 |
| GT200400121A (en) | 2005-03-03 |
| ZA200509132B (en) | 2007-02-28 |
| GB0314048D0 (en) | 2003-07-23 |
| OA13178A (en) | 2006-12-13 |
| TNSN05321A1 (en) | 2007-07-10 |
| RS20050924A (en) | 2008-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110434T1 (en) | N-PYRROLIDIN-3-YL-AMIDE PRODUCTS AS SEROTONIN AND NORADRENALINE | |
| NO20074093L (en) | Methods for Preparing Glucopyranosyl-Substituted Benzyl-Benzene Derivatives and Intermediates | |
| TW200635585A (en) | Monocyclic substituted methanones | |
| JO2871B1 (en) | Pyrrole compounds | |
| NO20055568L (en) | Substituted 1,4-diazepines and uses thereof | |
| WO2005037785A3 (en) | Derivatives of n-[phenyl(pyrrolidine-2-yl)methyl]benzamide and n-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | |
| NO20083598L (en) | Carbocyclic and heterocyclic arylsulfones as inhibitors of gamma secretase | |
| NO20084701L (en) | New heterocyclic compound or salt or intermediate thereof | |
| NO20072409L (en) | Substituted n-sulfonylaminobenzyl-2-phenoxy acetamide compounds | |
| BR112012032813A2 (en) | compound, pharmaceutical composition, and method for preventing, treating or ameliorating a disease or condition. | |
| WO2006086705B1 (en) | Substituted bis aryl and heteroaryl compounds as selective 5ht2a antagonists | |
| HUP0402604A2 (en) | Method for producing scopine esters | |
| WO2007071632A3 (en) | 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases | |
| EA201071012A1 (en) | DERIVATIVES OF AZETIDINE, METHOD OF THEIR RECOVERY AND USE OF THEM IN THERAPY | |
| NO20045701L (en) | Piperidine derivative, its preparation and use | |
| NO20060206L (en) | New azetidine compounds | |
| RU2009142997A (en) | 4-ALCOXYPYRIDAZINE DERIVATIVES AS FAST DISSOCIOUS DOPAMINE RECEPTOR 2 ANTAGONISTS | |
| TW200619215A (en) | Asymmetric synthesis of dihydrobenzofuran derivatives | |
| DE60324685D1 (en) | 2- (PHENYLTHIOMETHYL) - MORPHOLIN DERIVATIVES FOR USE AS SELECTIVE NOREPINEPHRINE RECOVERY INHIBITORS | |
| WO2008096586A1 (en) | Novel methylated catechin and composition containing the same | |
| BRPI0411603A (en) | 4- (Aminomethyl) piperidine benzamides as antagonists 5ht4 | |
| WO2009007536A8 (en) | Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics | |
| TW200505899A (en) | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | |
| NO20060190L (en) | <n-pyrrolidin-3-ylamide derivatives as serotonin and norepinephrine reuptake inhibitors | |
| NO20082226L (en) | 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |